Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02427308Withdrawn

Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

Role: lead

NCT05851547Phase 2Recruiting

Dose Escalation For INtraprostatic LEsions

Role: collaborator

NCT01050907Phase 2Completed

Miltefosine to Treat Mucocutaneous Leishmaniasis

Role: lead

NCT02429518Completed

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Role: lead

NCT02429505Withdrawn

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

Role: lead

NCT02431429Completed

Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Role: lead

All 6 trials loaded